ARCHIVES

Conversation With The Cancer Letter: PanCAN CEO Denies Bill Would Undermine NCI’s Role in Directing and Funding Research

This article is from The Cancer Letter archive.

Vol. 38 No. 31 | August 3, 2012

Download PDF Visit The Full Archive

Related Articles

Top NCI Officials Pledge No Further Consolidation of Clinical Trials System

December 5, 2014

In Brief: “…In Case Mrs. Lasker Happens To See A Senator”; White Potter Defend Center Progress

June 16, 1978

NCI Formaldehyde Finding Criticized

March 7, 1986

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

August 8, 1980

Bayer’s HER-2/neu Blood Test Cleared By FDA For Marketing.

December 15, 2000

Chop Analysis Shows Program Had Major Impact In Communities

January 25, 1985